Navigation Links
NxStage Medical Reports Third Quarter 2007 Results
Date:11/2/2007

LAWRENCE, Mass., Nov. 2 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), the manufacturer of the NxStage System One(TM) portable kidney dialysis machine, today announced its financial results for the third quarter ended September 30, 2007.

Revenues for the third quarter of 2007 were $11.6 million, compared to $5.5 million in the third quarter of 2006, an increase of 111%. Revenues in the chronic home dialysis market were $8.3 million for the third quarter of 2007, compared to $3.6 million in the third quarter of 2006. Revenues in the critical care market for the third quarter of 2007 were $3.3 million, compared to $1.9 million in the third quarter of 2006. For the nine months ended September 30, 2007 revenue was $30.0 million, a 123% increase over revenue of $13.5 million for the first nine months of 2006.

At the end of the third quarter of 2007, NxStage was working with 306 dialysis centers to provide home hemodialysis therapy with its System One to 1,957 end-stage renal disease (ESRD) patients. This compares to 265 centers and 1,615 patients at the end of the second quarter of 2007. NxStage also continued to expand use of the PureFlow SL to a broader customer base and at the end of the third quarter 2007, PureFlow penetration reached 65% of all System One machines in the chronic market. Expanding penetration of PureFlow among existing and new customers is an important element of NxStage's ongoing focus to improve margins.

"NxStage continues to validate the home hemodialysis opportunity and in the second quarter we demonstrated our ability to lead and grow this market," said Jeffrey H. Burbank, President & CEO of NxStage Medical. "Our recently completed acquisition of Medisystems mark
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...ogs have surprised researchers by showing that the...an toddlers. The study, by Austrian researchers,... when it comes to a physical problem-solving test....en researchers first observed how several children...
...tgrave, PhD, an expert on HIV prevention at the Jo...argeted campaign of testing and counseling aimed ...e effective than the mass patient screening propos...and Prevention (CDC). Holtgraves study is the fir...
...nday against South Korea's hard-drinking culture w...d economic losses, officials said . The campaign f...re to enhance public awareness of the dangers of e...ealth and Welfare said. "South Koreans consider o...
...heimer drug in the form of a milkshake. This milks...tarved by the damages of the Alzheimer disease . I...g large scale testing against the brain destroying...d Ketasyn, is a new approach to treating dementia....
Other Medicine News:Health News:Dogs Reasoning on Par With Human Toddlers: Study 2Health News:Targeted HIV Testing An Effective Way to Screen HIV Patients 2Health News:A Milky Alternative to Alzheimer Drug 2
(Date:9/3/2008)...Wrong Children Studied. Wrong,Conclusions Reached.... Centers for Disease,Control and Prevention (CDC) ...en the MMR vaccine and autism. The National Autism... dispel the growing public concern over a,vaccine-...cerning design,and methodology., For years, paren...
(Date:9/3/2008)...scular Disease Awareness Month, CHARLOTTESVILLE, ...cals,LLC, a clinical-stage drug-development compan...nmet medical needs, announced today that it has be...ial of its lead drug,candidate trans sodium crocet...the clinicaltrials.gov Website, is investigating T...
(Date:9/3/2008)... Phase 3 Plans with FDA, PRINCETON, N.J., Sept. 3...ed today that it successfully completed two key cl...new, innovative low-dose, once-weekly,contracepti...nal product,code AG-200-15. The Phase 2b safety an...oint of ovulation suppression, cycle control and s...
(Date:9/3/2008)...swire-FirstCall/ -- A sub-analysis of,the TRITON-T...rasugrel,compared with clopidogrel significantly r...(7.4 percent vs. 9.7 percent, p<0.0001), regardles...f an artery-opening,procedure known as percutaneou... spontaneously during the longer-term maintenance ...
Breaking Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Biannual Antibiotics May Cut Major Cause of Blindness in Africa 12290 1Biannual Antibiotics May Cut Major Cause of Blindness in Africa 12290 2NIST NCI SAIC partner on new method for detecting HER2 breast cancer 12288 1NIST NCI SAIC partner on new method for detecting HER2 breast cancer 12288 2DATATRAK International Management to Host Conference Call on February 26 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007 12285 1DATATRAK International Management to Host Conference Call on February 26 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007 12285 2DATATRAK International Management to Host Conference Call on February 26 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007 12285 3XTENT Announces 2007 Financial Results 12282 1XTENT Announces 2007 Financial Results 12282 2XTENT Announces 2007 Financial Results 12282 3XTENT Announces 2007 Financial Results 12282 4XTENT Announces 2007 Financial Results 12282 5XTENT Announces 2007 Financial Results 12282 6
....--(BUSINESS WIRE)--Apr 25, 2007 - BioDelivery,Sci... today,statistically significant results with BEMA... pain in its pivotal Phase III efficacy,clinical t...ievement of the primary efficacy endpoint of the t... compared to placebo., The results demonstrated th...
...mark; April 25, 2007 - Genmab A/S (CSE: GEN),annou...th,ofatumumab (HuMax-CD20™) in patients with...oral presentation at the 2007,Annual European Cong...n, which will include new results from the double-...umumab, along with data,from the previous interim ...
Other Medicine Technology:BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 2BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 3BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 4BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 5BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 6
Tank Blotting System. Designed for Western, Northern, or Southern Blotting. Transfer up to three gels with dimensions as large as 15cm x 21.5cm. Includes and internal cooling base for temperature
... proven electrophoretic transfer apparatus incorpo...ltimate in field uniformity. Its design allows for... when coupled with a low voltage power source such...ts/cm. The result is exceptionally rapid and exact...
...lot cell, a component of Bio-Rad's modular mini el...resis Systems), provides rapid, high-quality blott...ransfers two 7.5 x 10 cm gels in just 1 hour. Cool... absorbs heat generated during transfers. The Mini...
Includes PowerPac 200 power supply. Flexibility for a Range of Parameters. Quantitative Transfers. Native Enzyme, High Intensity, or Overnight Transfers. Faster, Higher-Efficiency Transfers via Pl
Medicine Products: